Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-07-17
2007-07-17
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S105000, C544S048000, C544S255000, C514S224200, C514S260100
Reexamination Certificate
active
10720844
ABSTRACT:
Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.
REFERENCES:
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 6069143 (2000-05-01), Ali et al.
patent: 6512099 (2003-01-01), Omura et al.
patent: 1 431 267 (2004-06-01), None
patent: 05-213985 (1993-08-01), None
patent: 2002-284741 (2002-10-01), None
patent: 2004-067635 (2004-03-01), None
patent: 2003-045230 (2003-06-01), None
patent: WO 01/32632 (2001-05-01), None
patent: WO 01/32632 (2001-05-01), None
patent: WO 03/016254 (2003-02-01), None
patent: WO 03/018536 (2003-03-01), None
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
Lin et al., Journal of Medicinal Chmeistry 22(6): 741-743, 1979.
Mirza et al., Journal of Chemical Societ Section C, Organic 3: 437-444, 1970. CA 72: 78966, 1970.
Chen et al., Trends in Cardiovascular Medicine 10: 188-192, 2000.
Chen et al. Arterioscler. Vasc. Biol. 25 (3): 482-486, 2005.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plym F., 20th edition vol. 1, 1004-1010, 1996.
Bagdade,Diabetes Reviews,5(4): 392-409 (1997).
Barone,Journal of Medicinal Chemistry,6: 39-42 (Jan. 1963).
Bast et al., “Imunostimulants”, Chapter 60, Section 16, pp. 790-799, inCancer Medicine,5thed: (Hamilton, Ontario, CA: B.C. Decker, 2000).
Berge et al.,Journal of Pharmaceutical Sciences,66(1): 1-19 (Jan. 1977).
Buhman et al.,Journal of Biological Chemistry,277(28): 25474-25479 (Jul. 12, 2002).
Cases et al.,Journal of Biological Chemistry,276(42): 38870-38876 (Oct. 19, 2001).
Cases et al.,Proc. Natl. Acad. Sci. USA,95: 13018-13023 (Oct. 1998).
Chen et al.,Diabetes,51: 3189-3195 (2002).
Chen et al.,Diabetes Reviews,5(4): 331-342 (1997).
Chen et al.,Journal of Clinical Investigation,109(8): 1049-1055 (Apr. 2002).
Chen et al.,Journal of Clinical Investigation,111: 1715-1722 (2003).
Chen et al.,Trends Cardiovasc. Med.,10(5): 188-192 (2000).
Chiasson et al.,Annals of Internal Medicine,121(12): 928-935 (Dec. 15, 1994).
Chung et al.,Planta Med.,70: 256-258 (2004).
Clemmons,Diabetes Reviews,5(4): 353-364 (1997).
Coniff et al.,American Journal of Medicine,98: 443-451 (May 1995).
Coniff et al.,Clinical Therapeutics 19(1): 16-26 (1997).
Farese et al.,Curr. Opin. Lipidol.,11: 229-234 (2000).
Garg et al.,Diabetes Reviews,5(4): 425-433 (1997).
Haffner,Diabetes Care,21(1): 160-178 (Jan. 1998).
Hsueh et al.,Diabetes Reviews,5(4): 343-352 (1997).
Iwamoto et al.,Diabetic Medicine,13(4); 365-370 (Apr. 1996).
Jokl et al.,Diabetes Reviews,5(4): 316-330 (1997).
Ko et al.,Archives of Pharmacal Research,25(4): 446-448 (2002).
Kwiterovich,The American Journal of Cardiology,82(12A): 3U-17U (Dec. 17, 1998).
Laakso et al.,Diabetes Reviews,5(4): 294-315 (1997).
Landauer et al.,Journal of Chemical Society:3721-3722 (1953).
Lee et al.,Planta Med,70: 197-200 (2004).
Lewis et al.,Endocrine Reviews,23(2): 201-229 (Apr. 2002).
Lopes-Virella et al.,Diabetes Reviews,5(4): 410-424 (1997).
Lyons et al.,Diabetes Reviews,5(4):365-391 (1997).
Mahler et al.,Journal of Clinical Endocrinology&Metabolism,84(4): 1165-1171 (Apr. 1999).
Malloy et al., “Chapter 4: A Risk Factor for Atherosclerosis: Triglyceride-rich Lipoproteins,”Advances in Internal Medicine,47: 111-136 (Mosby, Inc., 2001).
Nahm et al.,Tetrahedron Letters,22(39): 3815-3818 (1981).
Oelkers et al.,Journal of Biological Chemistry,273(41): 26765-26771 (Oct. 9, 1998).
Purnell et al.,Diabetes Reviews,5(4): 434-444 (1997).
Rustan et al.,Journal of Lipid Research,29: 1417-1426 (1988).
Smith et al.,Nature Genetics,25: 87-90 (May 2000).
Tomoda et al.,The Journal of Antibiotics,48(9): 937-941 (Sep. 1995).
Tomoda et al.,The Journal of Antibiotics,52(8): 689-694 (Aug. 1999).
Turner et al., “Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutic possibilities,”Progress in Drug Research,51: 33-94 (Basel, Switzerland: Birkhäuser Verlag, 1998).
United Kingdom Prospective Diabetes Study (UKPDS) Group,Diabetes Care,21(1): 87-92 (Jan. 1998).
Wermuth (ed.), “Molecular Variations Based on Isosteric Replacements,”The Practice of Medicinal Chemistry,13: 203-237 (London: Academic Press Limited, 1996).
Chen et al.,Diabetes,54(12): 3379-3386 (2005).
Gaziano et al.,Circulation,96: 2520-2525 (1997).
Kim et al.,J. Medicinal Chemistry,17(3): 369-371 (1974).
Robbins et al., “Blood Vessels” inPathologic Basis of Disease,6thed., W. B. Saunders Company: Philadelphia, 498-510 (1999).
Subauste et al.,Curr. Drug Targets Immune Endocr. Metabol. Disord.,3(4): 263-270 (2003).
Turkish et al.,J. Biol. Chem.,280(15): 14755-14764 (2005).
Vaziri et al.,Kidney Int.,66(1): 262-267 (2004).
Yu et al.,Hepatology,42(2): 362-371 (2005).
Fox Brian M.
Furukawa Noboru
Hao Xiaolin
Iio Kiyosei
Inaba Takashi
Balasubramanian Venkataraman
Japan Tobacco Inc.
Leydig , Voit & Mayer, Ltd.
LandOfFree
Fused bicyclic nitrogen-containing heterocycles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused bicyclic nitrogen-containing heterocycles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused bicyclic nitrogen-containing heterocycles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3734499